Panel vote points way to European approval for Tavneos

A positive decision from the European medicine regulator’s scientific panel makes another approval for the vasculitis med Tavneos (avacopan) likely.

Developed under license by Vifor Fresenius Medical Care Renal Pharma (VFMCRP), a joint venture of Vifor Pharma (SIX: VIFN) and Fresenius Medical Care, the therapy is being evaluated in combination with a rituximab or cyclophosphamide regimen.

The approval would cover treatment of adults with severe active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), the two main forms of ANCA-associated vasculitis.